PharmiWeb Recruiter Blog

Angelini

Angelini Pharma, a new partner in Epilepsy

PARIS--(BUSINESS WIRE)--On the occasion of World Epilepsy Day (14th of February 2022), Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy.

Read more
Labcorp

Labcorp Enters Comprehensive, Long-Term Laboratory Relationship With Ascension

  • Arrangement Includes Labcorp’s Acquisition of Certain Outreach Laboratory Assets
  • Strategic Collaboration Expands Patient Access to Labcorp’s Services, Drives Efficiencies and Advances Clinical Innovation

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into agreements to create a comprehensive strategic relationship with Ascension, one of the nation’s leading Catholic and non-profit health systems. Through the expansive strategic collaboration, Labcorp will manage Ascension’s hospital-based laboratories in 10 states and purchase select assets of the health system’s outreach laboratory business. This long-term relationship will expand Labcorp’s clinical laboratory services in several states across the country while creating opportunities to enhance care across all clinical areas.

Read more
East Coast USA’s Life Science Job Market

East Coast USA’s Life Science Job Market

USA’s East Coast is home to some of the largest Pharmaceutical and Life Science organisations in the world, including companies such as Johnson and Johnson, Merck, Celgene, BMS and more. Some of the strongest talent in the Life Science industry can be found here, with many of the country’s leading educational institutions located on the East Coast.

Read more
Sanofi

Sanofi completes acquisition of Amunix

ParisFebruary 8, 2022. Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The technology platform is highly complementary to Sanofi’s existing R&D platforms and supports Sanofi’s efforts to accelerate and expand its contributions to innovative medicines for oncology patients, with approximately 20 molecules currently in development.

Read more
Devyser

Devyser acquires Italian SmartSeq and strengthens position in genetic data analysis

Stockholm, February 7, 2022 - Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced that the company has utilized an option to acquire all of the remaining shares in the associated company SmartSeq S.r.l. ("SmartSeq"). The acquisition corresponds to 70% of shares in SmartSeq and the purchase consideration amounts to EUR 835,000, of which 29% in cash and 71% in newly issued Devyser shares. The acquisition strengthens Devyser's customer offering for diagnostic analysis and is expected to have a positive impact on Devyser's gross profit and gross margin.

Read more
Parexel

Parexel Extends Strategic Partnership with Medidata to Enhance Delivery of Decentralized Clinical Trials

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes company, announced today that Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, is extending their 15-year global strategic partnership. This builds upon the trusted relationship between the two companies and sets the goal of jointly pioneering a new era of decentralized clinical trial technology (DCT) for the life sciences industry.

Read more